top of page

WELCOME TO
NOSEVAC

The international partnership to advance the development of new vaccines against upper respiratory tract pathogens

The NOSEVAC project aims at developing and evaluating innovative nasal vaccine platforms as a novel approach to prevent the earliest stage of infection, thereby inhibiting upper respiratory tract (URT) colonisation, transmission and disease.

Under the European Vaccine Initiative (EVI) coordination, the NOSEVAC project builds on a unique consortium of 13 complementary teams from the EU, UK and Switzerland.

NOSEVAC background.png

Are you in Rome and interested in nasal vaccines? Don't miss the hance to attend NOSEVAC open session! 

NOSEVAC Logo white.png

When?  21.04.2026, 09:00 - 11:00 a.m.

Where? Aula Nitti Bovet - Istituto Superiore di Sanità (ISS), Rome

Asset 4.png

Advancing mucosal vaccines:

Science, strategy, and society

  • Introduction to NOSEVAC project by Ali M. Harandi (European Vaccine Initiative)

​​

  • Keynote speaker: Crosstalk of systemic and mucosal B-cell immunity for protection of the respiratory tract by Rita Caersetti (Bambino Gesù Children’s Hospital)

 

  • Exploring innate immune response in vaccinology: from ex vivo to in vitro standpoint by Eliana Coccia (Istituto Superiore di Sanità)

 

  • How to tackle vaccine hesitancy? Lessons from health psychology research by Jocelyn Raude, NOSEVAC SEAC member (UMR ARENES / École des hautes études en santé publique)

Acceptability of a Nasal Vaccine Among Healthcare Professionals in France 

Enquête : acceptabilité du vaccin nasal par les professionnels de santé

Dans le cadre du projet européen NOSEVAC, nous menons une recherche sur les aspects psychologiques et comportementaux liés à l’acceptabilité du vaccin nasal.

 

Nous avons élaboré une enquête en ligne d’une durée d’environ 10 minutes à destination de professionnels de santé en France, susceptibles d’administrer et/ou de prescrire des vaccins (Médecin, infirmier·ère, sage-femme, pharmacien·ne).

AT A GLANCE

TIMELINE

1 May 2023

to 30 April 2028

COORDINATOR

European Vaccine Initiative (EVI)

FUNDER

European Union,

UKRI and SERI

FUNDING

€11.6 Million

The project focuses on four major respiratory pathogens: Streptococcus pneumoniae or pneumococcus, Bordetella, influenza virus, and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), responsible for diseases with major impact on public health: community-acquired pneumonia (CAP), whooping cough, influenza and Coronavirus Disease 2019 (COVID-19), respectively.

NOSEVAC aims to combine innovative formulations and manufacturing processes to deliver and evaluate bivalent RNA- and protein-based nasal vaccines against bacterial and viral infection, respectively.

bottom of page